scholarly journals Role of Gut Microbiota on Cardio-Metabolic Parameters and Immunity in Coronary Artery Disease Patients with and without Type-2 Diabetes Mellitus

2017 ◽  
Vol 8 ◽  
Author(s):  
Lidia Sanchez-Alcoholado ◽  
Daniel Castellano-Castillo ◽  
Laura Jordán-Martínez ◽  
Isabel Moreno-Indias ◽  
Pilar Cardila-Cruz ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Type 2 Diabetes Mellitus ◽  
Coronary Artery ◽  
Gut Microbiota ◽  
Metabolic Parameters ◽  
Artery Disease

scholarly journals Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association

Circulation ◽  
2020 ◽  
Vol 141 (19) ◽  
Author(s):  
Suzanne V. Arnold ◽  
Deepak L. Bhatt ◽  
Gregory W. Barsness ◽  
Alexis L. Beatty ◽  
Prakash C. Deedwania ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Type 2 Diabetes Mellitus ◽  
Coronary Artery ◽  
Cardiovascular Outcomes ◽  
Artery Disease ◽  
Selection Of

Although cardiologists have long treated patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a comorbidity that affected the development and progression of the disease. Over the past decade, a number of factors have shifted that have forced the cardiology community to reconsider the role of T2DM in CAD. First, in addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a number of treatment choices for CAD. In this document, we discuss the role that T2DM has in the selection of testing for CAD, in medical management (both secondary prevention strategies and treatment of stable angina), and in the selection of revascularization strategy. Second, although glycemic control has been recommended as a part of comprehensive risk factor management in patients with CAD, there is mounting evidence that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. In this document, we discuss the role of glycemic management (both in intensity of control and choice of medications) in cardiovascular outcomes. It is becoming clear that the cardiologist needs both to consider T2DM in cardiovascular treatment decisions and potentially to help guide the selection of glucose-lowering medications. Our statement provides a comprehensive summary of effective, patient-centered management of CAD in patients with T2DM, with emphasis on the emerging evidence. Given the increasing prevalence of T2DM and the accumulating evidence of the need to consider T2DM in treatment decisions, this knowledge will become ever more important to optimize our patients’ cardiovascular outcomes.

The role of lnc-DC long non-coding RNA and SOCS1 in the regulation of STAT3 in coronary artery disease and type 2 diabetes mellitus

2018 ◽  
Vol 32 (3) ◽  
pp. 258-265 ◽  
Author(s):  
Asieh Alikhah ◽  
Majid Pahlevan Kakhki ◽  
Amirhossain Ahmadi ◽  
Reyhaneh Dehghanzad ◽  
Mohammad Ali Boroumand ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Type 2 Diabetes Mellitus ◽  
Coronary Artery ◽  
Non Coding Rna ◽  
Artery Disease ◽  
Long Non Coding Rna

scholarly journals Evaluating molecular study of the association of Glutathione S – Transferase GST (T1 , M1) genetic polymorphism in Iraqi Arab Femals with Type 2 Diabetes Mellitus and Coronary Artery Disease

2015 ◽  
Vol 12 (4) ◽  
pp. 715-723
Author(s):  
Baghdad Science Journal
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Type 2 Diabetes Mellitus ◽  
Coronary Artery ◽  
Lipid Profiles ◽  
Glutathione S Transferase ◽  
Artery Disease

Coronary artery disease (CAD) is a major health concern and leading of death in individuals with type 2 diabetes mellitus (T2DM). Glutathione S – Transferase(GST) are known for their broad range of detoxification and in the metabolism of xenobiotics . The role of functional variants of these genes in the development of various disorder is proven. We investigated the possible role of these variants in the development of CAD in T2DM patients. In this case – control study a total of 60 patients (T2DM = 30 ; T2DM – CAD = 30) and 30 controls were included. Serum lipid profiles were measured and DNA was extracted from the blood samples. Multiplex PCR for GSTT1/M1 (present / null) polymorphism, were performed for genotyping of study participants. Gene frequency and lipid profiles were statistically analyzed for disease association. Regression analysis showed that, there was no significant difference of the frequency of GSTT1 (positive /null) genotype and GSTM1 (positive /null) genotype in the 3 study groups . GSTT1 – positive genotype is associated with a 0.51 fold increased ( OR = 0.51 ; 95%CI = 2- 0.1 ;P = 0.321 ) , while the GSTM1 – positive genotype was associated with a 3 fold increase ( OR = 3.06 ; 95%CI=1- 9.7 ; P = 0.055) .We conclude GSTT1 positive genotype considered to be a protective risk from CAD in T2DM patients . The GSTM1 – positive genotype it was considered to be a risk factor of the CAD in T2DM patients.

Sign in / Sign up

Export Citation Format

Share Document